What is Brymill Cryogenic Systems?
Established in 1966, Brymill Cryogenic Systems operates as a premier manufacturer of hand-held liquid nitrogen cryosurgical and cryospray devices. The company is widely recognized for its Cry-Ac and Cry-Ac-3 product lines, which provide healthcare providers with the controlled application of liquid nitrogen necessary for the treatment of various lesions. With a client base spanning physicians, nurse practitioners, and veterinarians, Brymill has cultivated a reputation for reliability and clinical precision.
Beyond hardware manufacturing, the firm distinguishes itself by offering comprehensive training, documentation, and technical support. This holistic approach to product lifecycle management ensures that practitioners can effectively integrate cryosurgical solutions into their clinical workflows, thereby cementing Brymill's status as a foundational entity in the medical instrumentation market.
How much funding has Brymill Cryogenic Systems raised?
Brymill Cryogenic Systems has raised a total of $496K across 2 funding rounds:
Debt
$150K
Debt
$346K
Debt (2020): $150K with participation from PPP
Debt (2021): $346K led by PPP
Key Investors in Brymill Cryogenic Systems
PPP
Public-Private Partnership
What's next for Brymill Cryogenic Systems?
With the recent capital deployment, Brymill Cryogenic Systems is well-positioned to accelerate its strategic growth initiatives. The company is expected to focus on expanding its global footprint and potentially diversifying its product portfolio to address evolving clinical requirements. By leveraging its long-standing industry expertise, Brymill aims to optimize its supply chain and enhance its digital support infrastructure, ensuring that its cryosurgical devices remain the gold standard for practitioners worldwide.
The focus moving forward will likely involve scaling manufacturing efficiencies to accommodate increased demand while maintaining the rigorous quality standards that have defined the brand for over five decades. As the medical device industry continues to prioritize minimally invasive procedures, Brymill's commitment to innovation and clinical efficacy will be paramount in sustaining its long-term growth trajectory and market leadership.
